Global expansion
Expanding toward the patients clinical research keeps missing.
Our roadmap is deliberately sequenced: strengthen the Americas corridor, then open Asia Pacific. Each market entry follows the same discipline that built our Ponce operation.
Footprint & expansion corridors
Hover a node for detail
- Operating
- Expanding
- Planned
Ponce, Puerto Rico
Headquarters · Phase 1 capable unit · Metro Pavia Health Systems partnership
Roadmap
Three stages, each earned before the next begins.
Stage 01 · Operating
Puerto Rico
Ponce as the operational core — headquarters, Phase 1 unit and Caribbean access point, anchored by the Metro Pavia Health Systems partnership.
- US regulatory framework
- Phase 1 unit capability
- Bilingual coordinator teams
Stage 02 · Expanding
Latin America
Site identification, investigator partnerships and regulatory pathway mapping across priority markets with large, under-enrolled patient populations.
- Colombia & Mexico priority
- Southern Cone assessment
- Regional monitoring hub design
Stage 03 · Planned
Philippines
Asia-Pacific gateway with English-language clinical infrastructure, strong physician networks and growing sponsor interest in regional diversity data.
- Phase 1 footprint intent
- Local partnership pipeline
- Ethics & regulatory groundwork
Why these markets
Diverse populations, real disease burden, underused capacity.
Sponsors increasingly need enrollment diversity that holds up to regulatory scrutiny. Our target regions offer it alongside physician networks eager for research participation.
Population diversity
Hispanic/Latino and Asian-Pacific representation that strengthens generalizability.
Chronic disease prevalence
High burden in diabetes, wound care, cardiology and renal disease across target markets.
Capacity, not saturation
Fewer competing trials per eligible patient than in saturated metro research markets.
One standard, many geographies
Expansion only counts if the data holds up everywhere.
Each new market is activated against the same documentation, training and monitoring standard we run today — sequenced deliberately rather than announced early.
Next step
Planning a multi-region study?
Tell us the geographies you need. We'll show you where Aspira can deliver today and where we can be ready on your timeline.